Cabozantinib for Patients With Recurrent or Progressive Meningioma

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04081701` - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.	Phase 4
Recruiting	`NCT03631953` - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	Phase 1
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT04367779` - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn	`NCT00985036` - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients	N/A
Completed	`NCT01347307` - Stereotactic Body Radiotherapy for Spine Tumors	N/A
Completed	`NCT01811524` - The Etiology and Progression of Brain Tumors	N/A
Completed	`NCT03648034` - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality	N/A
Recruiting	`NCT06036706` - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:	N/A
Recruiting	`NCT06014905` - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma	Phase 1
Not yet recruiting	`NCT04386642` - Tranexamic Acid Reduce Blood Loss in Meningioma Resection	Phase 4
Active, not recruiting	`NCT04595786` - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection	N/A
Completed	`NCT04305470` - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma	Phase 3
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Not yet recruiting	`NCT02978677` - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas	N/A
Active, not recruiting	`NCT02933736` - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients	Early Phase 1
Completed	`NCT02267928` - Information Presentation Formats	N/A
Completed	`NCT00589784` - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Phase 2
Active, not recruiting	`NCT03071874` - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	Phase 2
Recruiting	`NCT05416567` - Embolization for Meningioma	N/A

NCT number	NCT05425004
Study type	Interventional
Source	Baptist Health South Florida
Contact	Rupesh R Kotecha, M.D.
Phone	(786) 596-2000
Email	rupeshk@baptisthealth.net
Status	Recruiting
Phase	Phase 2
Start date	May 27, 2022
Completion date	May 2028

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms